| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FKBP1B |
| Uniprot No | P68106 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-108aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHRSMGVEIETISPGDGRTFPKKGQTCVVHYT GMLQNGKKFDSSRDRNKPFKFRIGKQEVIKGFEEGAAQMSLGQRAKLTCT PDVAYGATGHPGVIPPNATLIFDVELLNLE |
| 预测分子量 | 14 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于FKBP1B(又称FKBP12.6)重组蛋白研究的示例参考文献(内容为假设性概括，仅供参考)：
---
1. **文献名称**：*"FKBP12.6 Stabilizes Cardiac Ryanodine Receptors and Regulates Calcium Release in Cardiomyocytes"*
**作者**：Wei, X.H. et al.
**摘要**：通过重组FKBP1B蛋白实验，揭示了其与心肌细胞Ryanodine受体(RyR2)的结合能力，证明FKBP1B通过稳定RyR2通道的关闭状态，防止钙泄漏，从而减少心律失常风险。
2. **文献名称**：*"Structural and Functional Analysis of Recombinant FKBP12.6 in RyR2 Modulation"*
**作者**：Yamazaki, M. et al.
**摘要**：利用重组FKBP1B蛋白进行X射线晶体学分析，解析其与RyR2的互作结构，发现特定突变会破坏结合能力，导致钙信号失调，为遗传性心脏病机制提供依据。
3. **文献名称**：*"Recombinant FKBP12.6 as a Therapeutic Target for Heart Failure"*
**作者**：McKinsey, T.A. et al.
**摘要**：研究重组FKBP1B蛋白在心力衰竭模型中的作用，表明其过表达可改善心肌钙稳态，逆转病理重塑，提示其作为潜在治疗靶点。
4. **文献名称**：*"FKBP1B Recombinant Protein Enhances Drug Screening for RyR2 Stabilizers"*
**作者**：Stamler, J.S. et al.
**摘要**：开发基于重组FKBP1B蛋白的高通量药物筛选平台，鉴定出小分子化合物可增强FKBP1B与RyR2的结合，为治疗钙相关心脏疾病提供新策略。
---
**备注**：以上文献为示例，实际研究中请通过学术数据库(如PubMed、Web of Science)检索真实论文。FKBP1B的研究多聚焦于其与RyR2的互作及在心脏疾病中的调控作用，重组蛋白常被用于结构、功能及药物开发研究。
FKBP1B (FK506-binding protein 1B), also known as FKBP12.6. is a member of the FKBP immunophilin family characterized by its ability to bind immunosuppressive drugs like FK506 (tacrolimus) and rapamycin. This protein is encoded by the *FKBP1B* gene in humans and shares high sequence homology with FKBP12 (FKBP1A), though it lacks the TPR (tetratricopeptide repeat) domain found in some larger FKBPs. Structurally, FKBP1B contains a conserved FK506-binding domain that confers peptidyl-prolyl cis-trans isomerase (PPIase) activity, facilitating protein folding and conformational regulation.
Functionally, FKBP1B is best known for its role in modulating intracellular calcium signaling by interacting with ryanodine receptors (RyRs), particularly RyR2 in cardiac and skeletal muscle. This interaction stabilizes RyR2 channels, preventing aberrant calcium leakage that can disrupt excitation-contraction coupling. Dysregulation of FKBP1B-RyR2 binding has been implicated in cardiac arrhythmias, heart failure, and muscular disorders.
Recombinant FKBP1B protein is produced using expression systems like *E. coli* or mammalian cells, often fused with tags (e.g., His-tag) for purification. Its applications span drug discovery, structural studies, and disease mechanism research. In cancer, FKBP1B overexpression has been linked to chemoresistance, while in neurodegenerative diseases, it may influence tau protein aggregation. The protein also serves as a tool to study immunosuppressant drug interactions and calcium-dependent pathways. Recent studies explore its potential as a therapeutic target for conditions like cardiac hypertrophy and Alzheimer’s disease.
×
